NCT00135629View on ClinicalTrials.gov

Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

January 31, 2008

Study Completion Date

October 31, 2008

Conditions
Rhinitis, Allergic, Seasonal
Interventions
BIOLOGICAL

Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).

Active injections of alum-adsorbed grass pollen vaccine (Alutard SQ).

OTHER

Placebo Injection

Placebo Injection

PROCEDURE

Venepuncture: 100ml blood sample taken on 12 separate visits

Venepuncture: 100ml blood sample taken on 12 separate visits

Trial Locations (1)

SW3 6LY

Royal Brompton Hospital, NHLI Imperial College, London

All Listed Sponsors
collaborator

ALK-Abelló A/S

INDUSTRY

lead

Imperial College London

OTHER

NCT00135629 - Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever | Biotech Hunter | Biotech Hunter